Skip to main content
All Posts By

Webmaster

Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA)

By Palvella Therapeutics, Portfolio News
Palvella Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts …
Read More

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

By Portfolio News, Palvella Therapeutics
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 million of cash and…
Read More